JRJussi Rytkönen

Jussi Rytkönen

*This is an algorithmically generated author record based on publicly available information.

Jussi Rytkönen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Functional ultrasound imaging can detect vascular changes in tau P301S mouse model of Alzheimer’s disease

    by Jussi Rytkönen, Artem Shatillo, Mateusz Dudek, Jukka Puoliväli, Juho Oksman, Teija Parkkari, Diana Miszczuk, Cindy Yang, Steven P Braithwaite, S. Sakura Minami

    Background: Tauopathies are neurodegenerative disorders characterized by the accumulation of abnormal tau protein leading to cognitive and/or motor dysfunction. Evidence suggests that tauopathy mouse models develop changes in blood vessel morphology, density and altered cerebral blood flow, which could be linked to cognitive deficits in Alzheimer’s Disease. Here we assess changes in neurovascular coupling in Tau P301S mouse model (MAPT P301S, PS19) using functional ultrasound (fUS) and its relationship to histological changes and cognitive deficits.Method: Hemizygous (HE) P301S mice and their wild type littermates (n=20) were used in the study. fUS imaging of the brain was performed at 6 and 7 months of age, including resting state functional connectivity (RFC), somatosensory stimulation and acetazolamide challenge (ACZ, 30 mg/kg). At 7 months contextual fear conditioning (CFC) and radial arm water maze (RAWM) tests were used to assess behavioral impairments. At study end, brains were histologically assessed for microgliosis and synaptic density.Result: At 6 months of age, fUS imaging showed differences between genotypes in all measurements. Resting state imaging showed a reduction in RFC of sensory‐motor cortex of HE animals. Chemical stimulation showed strong vascular reaction in HE mice after ACZ challenge. Somatosensory stimulation resulted in lower response in HE mice compared to WT. The fUS data at 7 months had a lower signal‐to‐noise ratio compared to 6 months, but similar trends were observed. In RAWM HE mice made less errors and displayed a trend toward increased latency in finding the platform compared to WT. The progression pattern of HE animals during CFC differed from WT counterparts. Significant increases in microgliosis by CD68 immunostaining were observed in HE mice, accompanied by a significant reduction in synapse density.Conclusion: fUS is a powerful tool for functional imaging of preclinical CNS disease models. Here we confirmed vascular changes in P301S mouse model accompanied by mild decline in cognition and significant effects on neuroinflammation and synaptic density.

  • Efficacy of RAA7 treatment in TG4510 mouse model of Alzheimer's disease

    by Chin‐Yin Tai, Ming‐Kuei Jang, Taina‐Kaisa Stenius, Kaisa Paldanius, Jukka Puoliväli, Jussi Rytkönen, Juho Oksman, Teija Parkkari, Tuulia Huhtala, Leena Rauhala, et al.

    Background: Tauopathies are neurodegenerative characterized by the accumulation of abnormal phosphorylated and aggregated forms of Tau protein in the brain. rTg4510 (MAPT*P301L) mouse model is a widely used tauopathy model for studying therapeutic intervention that target neurodegeneration and tau pathology.Method: In this study rTg4510 mice (n=13‐15/group) were treated with RAA7 (10 mg/kg and 50 mg/kg) or vehicle (PBS). At 7 months of age tau pathology and neurodegeneration was characterized using cresyl fast violet staining (CFV) and NeuN for neurodegeneration, total human Tau (HT7) and phosphorylated human Tau (AT8). Sections were analyzed as % of area of positive signal. Four regions of interest were examined: cortex, CA1 and dentate gyrus regions and whole hippocampus.Result: Our results showed that RAA7 treatment diminish neurodegeneration and affect tau pathology. In CFV and NeuN staining, RAA7 10 mg/kg increased % of stained area in all analyzed brain regions, whereas RAA7 50 mg/kg in the CA1 region when compared to PBS group. In addition, high dose treatment showed neuroprotective effect in the DG regions of hippocampus as well. NeuN/CFV ratio was decreased by RAA7 10 mg/kg treatment in all analyzed areas. Assessment of tau expression revealed that RAA7 10 mg/kg decreased level of total Tau in CA1 region and phosphorylated Tau in cortex when compared to PBS group. Unexpectedly, RAA7 50 mg/kg showed significantly higher total tau level in the whole hippocampus when compared to PBS group, and no effect on the tau phosphorylation level.Conclusion: In conclusion, RAA7 treatment showed neuroprotective in Tg4510 mice demonstrated by reduced Tau accumulation and phosphorylation driven inhibition of neuronal cell death.

  • Open Access

    Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors

    by Tuulia Huhtala, Pekka Poutiainen, Jussi Rytkönen, Kimmo Lehtimäki, Teija Parkkari, Iiris Kasanen, Anu J. Airaksinen, Teija Koivula, Patrick Sweeney, Outi Kontkanen, et al.

    Dopamine receptors are involved in pathophysiology of neuropsychiatric diseases, including Huntington’s disease (HD). PET imaging of dopamine D2 receptors (D2R) in HD patients has demonstrated 40% decrease in D2R binding in striatum, and D2R could be a reliable quantitative target to monitor disease progression. A D2/3R antagonist, [18F] fallypride, is a high-affinity radioligand that has been clinically used to study receptor density and occupancy in neuropsychiatric disorders. Here we report an improved synthesis method for [18F]fallypride. In addition, high molar activity of the ligand has allowed us to apply PET imaging to characterize D2/D3 receptor density in striatum of the recently developed zQ175DN knock-in (KI) mouse model of HD. We longitudinally characterized in vivo [18F] fallypride -PET imaging of D2/D3 receptor densities in striatum of 9 and 12 month old wild type (WT) and heterozygous (HET) zQ175DN KI mouse. Furthermore, we verified the D2/D3 receptor density in striatum with [3H] fallypride autoradiography at 12 months of age. We implemented an improved synthesis method for [18F] fallypride to yield high molar activity (MA, 298–360 GBq/μmol) and good reproducibility. In the HET zQ175DN KI mice, we observed a significant longitudinal decrease in binding potential (BPND) (30.2%, p < 0.001, 9 months of age and 51.6%, p < 0.001, 12 months of age) compared to WT littermates. No mass effect was observed when the MA of [18F] fallypride was > 100 GBq/μmol at the time of injection. Furthermore, the decrease of D2/D3 receptor density in striatum in HET zQ175DN KI was consistent using [3H] fallypride autoradiography. We observed a significant decrease in D2/D3R receptor densities in the striatum of HET zQ175DN KI mice compared to WT mice at 9 and 12 months of age. These results are in line with clinical findings in HD patients, suggesting [18F] fallypride PET imaging has potential as a quantitative translational approach to monitor disease progression in preclinical studies.


  • Open Access

    A multimodal approach to identify clinically relevant parameters to monitor disease progression in a preclinical model of neuropediatric disease

    by Tyler B. Johnson, Jon J. Brudvig, Kimmo K. Lehtimäki, Jacob T. Cain, Katherine A. White, Timo Bragge, Jussi Rytkönen, Tuulia Huhtala, Derek Timm, Maria Vihma, et al.

    While research has accelerated the development of new treatments for pediatric neurodegenerative disorders, the ability to demonstrate the long-term efficacy of these therapies has been hindered by the lack of convincing, noninvasive methods for tracking disease progression both in animal models and in human clinical trials. Here, we unveil a new translational platform for tracking disease progression in an animal model of a pediatric neurodegenerative disorder, CLN6-Batten disease. Instead of looking at a handful of parameters or a single “needle in a haystack”, we embrace the idea that disease progression, in mice and patients alike, is a diverse phenomenon best characterized by a combination of relevant biomarkers. Thus, we employed a multi-modal quantitative approach where 144 parameters were longitudinally monitored to allow for individual variability. We use a range of noninvasive neuroimaging modalities and kinematic gait analysis, all methods that parallel those commonly used in the clinic, followed by a powerful statistical platform to identify key progressive anatomical and metabolic changes that correlate strongly with the progression of pathological and behavioral deficits. This innovative, highly sensitive platform can be used as a powerful tool for preclinical studies on neurodegenerative diseases, and provides proof-of-principle for use as a potentially translatable tool for clinicians in the future. One Sentence Summary: Principal component analysis identifies a set of clinically relevant parameters able to measure progression of Batten disease in a mouse model.